Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 194 participants.
Also called NCT01096667
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 194 participants
- Sponsor
- Registry
-
NCT01096667
-
- Other papers using this trial's data
- Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01096667. Randomized; double masking; primary purpose treatment. Start 2010-05-17 (actual); primary completion 2011-02-09 (actual). Results posted on 2017-12-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Hypertension
- Intervention (Drug)
- Placebo to Ertuglilflozin 1 or 5 mg
- Intervention (Drug)
- Ertugliflozin 1 mg
- Intervention (Drug)
- Ertugliflozin 5 mg
- Intervention (Drug)
- Ertugliflozin 25 mg
- Intervention (Drug)
- HCTZ 12.5mg
- Intervention (Drug)
- Placebo to HCTZ
- Intervention (Drug)
- Placebo to ertuglilflozin 25 mg
- Lead sponsor
- Merck Sharp & Dohme LLC
- Collaborator
- Pfizer
Record details
- Record id
cardio:ct-nct01096667- Content hash
454573487a61cf1174c7fe17b432990d9b8910f9ec04881a36a1b6afd5b370c0